GlassScriptPhysician profile
Matthew C Irvin
NPI 1043644040
$9,181.05
in general payments reported to CMS, 2019-2025
24 companies · $772 in 2025
The $772 reported for 2025 was more than what 85% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $148 · 2020: $79.91 · 2021: $721 · 2022: $1,846 · 2023: $4,964 · 2024: $651 · 2025: $772.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,862 · Food and Beverage: $2,525.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,861.63 |
| Food and Beverage | $2,525.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Relievant Medsystems, INC. | $2,970.26 | 2021-2023 | Intracept |
| Boston Scientific Corporation | $2,940.12 | 2019-2025 | Intracept, General - Pain Management |
| Medtronic, INC. | $1,092.04 | 2021-2023 | Intellis Adaptivestim, Synchromedii |
| Aurora Spine, INC. | $381.96 | 2022 | |
| Lundbeck LLC | $212.96 | 2023-2025 | Vyepti |
| Pfizer INC. | $200.63 | 2020-2025 | |
| Abbvie INC. | $199.35 | 2022-2025 | |
| Protega Pharmaceutials INC | $195.11 | 2024-2025 | Roxybond |
| Collegium Pharmaceutical, INC. | $186.74 | 2022-2025 | Belbuca |
| Averitas Pharma INC. | $165.61 | 2023-2025 | Qutenza |
| Allergan, INC. | $101.33 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $96.78 | 2022 | |
| Indivior INC. | $96.21 | 2024-2025 | Sublocade |
| Idorsia Pharmaceuticals US INC | $59.75 | 2023-2024 | Quviviq |
| Spr Therapeutics, INC | $45.66 | 2025 | Sprint Pns System |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grt US Holding, INC. | $43.53 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.25 | 2021-2022 | |
| Amgen INC. | $41.05 | 2019-2020 | |
| Axsome Therapeutics, INC. | $30.77 | 2024 | Sunosi |
| Merck Sharp & Dohme LLC | $20.18 | 2025 | Verquvo |
| Vertex Pharmaceuticals Incorporated | $17.64 | 2024 | |
| Lilly USA, LLC | $15.69 | 2020 | |
| Horizon Therapeutics Plc | $13.38 | 2019 | |
| Fidia Pharma USA INC. | $11.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Irvin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.